Cargando…

Immune checkpoint inhibitor administration during pregnancy: a case series

BACKGROUND: Immune checkpoint inhibitors have been widely implemented in current clinical practice. Although cancer occurs in ∼1 out of 1000 pregnancies, treatment remains challenging. Until now, limited data exist regarding immunotherapy administration during pregnancy. This systemic review aims to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andrikopoulou, A., Korakiti, A.M., Apostolidou, K., Dimopoulos, M.A., Zagouri, F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8426195/ https://www.ncbi.nlm.nih.gov/pubmed/34487972 http://dx.doi.org/10.1016/j.esmoop.2021.100262

Ejemplares similares

Trastuzumab administration during pregnancy: an update
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Correction to: Trastuzumab administration during pregnancy: an update
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Germline mutations in a clinic-based series of pregnancy associated breast cancer patients
por: Zografos, Eleni, et al.
Publicado: (2021)

MicroRNAs as Potential Predictors of Response to CDK4/6 Inhibitor Treatment
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

The emerging role of BET inhibitors in breast cancer
por: Andrikopoulou, A., et al.
Publicado: (2020)

The Genomic Profile of Pregnancy-Associated Breast Cancer: A Systematic Review
por: Korakiti, Anna-Maria, et al.
Publicado: (2020)

CDK4/6 Inhibitors and Arthralgia: A Single Institution Experience
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

How we treat endocrine complications of immune checkpoint inhibitors
por: Paschou, S.A., et al.
Publicado: (2021)

TP53 mutations determined by targeted NGS in breast cancer: a case-control study
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Aromatase and CDK4/6 Inhibitor-Induced Musculoskeletal Symptoms: A Systematic Review
por: Andrikopoulou, Angeliki, et al.
Publicado: (2021)

Long-Term Neurodevelopmental Outcome of Children after in Utero Exposure to Chemotherapy
por: Korakiti, Anna-Maria, et al.
Publicado: (2020)

Germline and somatic variants in ovarian carcinoma: A next-generation sequencing (NGS) analysis
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

Impact of CDK4/6 Inhibitors on Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS) in the Adjuvant Setting
por: Skafida, Efthymia, et al.
Publicado: (2023)

Immune checkpoint inhibitors in liver transplant: a case series
por: Rudolph, Mark, et al.
Publicado: (2023)

SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition
por: Terpos, Evangelos, et al.
Publicado: (2022)

Case series: Immune checkpoint inhibitor-induced transverse myelitis
por: Chatterton, Sophie, et al.
Publicado: (2023)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis
por: Park, Changhee, et al.
Publicado: (2019)

Immune checkpoint inhibitor myocarditis with complete heart block: a case series
por: O'shea, M, et al.
Publicado: (2023)

Supportive medication in cancer during pregnancy
por: Zagouri, Flora, et al.
Publicado: (2020)

A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients
por: Nair, Viswam S., et al.
Publicado: (2021)

What to expect from paraneoplastic syndromes of the nervous system in uterine cancer: A review of the literature
por: Svarna, Anna, et al.
Publicado: (2023)

Clinical Perspectives of ERCC1 in Bladder Cancer
por: Koutsoukos, Konstantinos, et al.
Publicado: (2020)

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: Case Series and Review of the Literature
por: Agrawal, Nikhil, et al.
Publicado: (2019)

Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: a seminal case series
por: Moseley, Kendall F., et al.
Publicado: (2018)

Apremilast for immune checkpoint inhibitor-induced psoriasis: A case series
por: Mayor Ibarguren, Ander, et al.
Publicado: (2021)

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
por: Coustal, Cyrille, et al.
Publicado: (2023)

Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
por: Peiffert, Mathilde, et al.
Publicado: (2021)

Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series
por: Chye, Adrian M., et al.
Publicado: (2022)

Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series
por: Zagouri, F, et al.
Publicado: (2013)

Celiac Disease After Administration of Immune Checkpoint Inhibitors: A Case Report
por: Leblanc, Julie, et al.
Publicado: (2021)

Oncological Patients With Endocrine Complications After Immunotherapy With Checkpoint Inhibitors Present Longer Progression-Free and Overall Survival
por: Paschou, Stavroula A., et al.
Publicado: (2022)

Immune checkpoint inhibitor-induced encephalitis with dostarlimab in two patients: Case series
por: Marzoughi, Sina, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors’ Associated Renal Toxicity: A Series of 12 Cases
por: Palamaris, Kostas, et al.
Publicado: (2022)

Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series
por: Zhang, Robert S., et al.
Publicado: (2021)

Oligometastatic Melanoma Treated by Metastasectomy in Combination with Immune Checkpoint and BRAF Inhibitors: A Case Series
por: Palmer, John P., et al.
Publicado: (2023)

“The emerging role of capivasertib in breast cancer”
por: Andrikopoulou, Angeliki, et al.
Publicado: (2022)

A case of severe acute hemorrhagic duodenitis after administration of immune checkpoint inhibitor
por: Saito, Keita, et al.
Publicado: (2021)

SJS/TEN immune-related dermatologic reaction secondary to immune checkpoint inhibitor pembrolizumab in skin of color
por: Pierre, A.B., et al.
Publicado: (2023)

Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment
por: Abu-Sbeih, Hamzah, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s2ace3coietddjo6japmpc8r8o